Del Giudice M E, Sawka C A, Pritchard K I, Llewellyn-Thomas H A, Trudeau M E, Lewis J E, Franssen E
Department of Family and Community Medicine, University of Toronto, Toronto, Ontario, Canada.
Breast Cancer Res Treat. 2003 May;79(2):213-23. doi: 10.1023/a:1023951616696.
Physician support is required for successful patient recruitment to a large randomized controlled trial (RCT) designed to determine the safety and benefits of short-term hormone replacement therapy (HRT) after breast cancer (BC).
A survey was mailed to 1899 Canadian gynaecologists, family physicians, medical, radiation and surgical oncologists to assess willingness to refer patients to an RCT of HRT after BC.
Of 538 physicians, 420 (78%) reported that they would be willing to refer a woman after BC to an RCT of HRT versus placebo. Variables predicting willingness to refer included: support for HRT in well women (p = 0.04) and after BC (p = 0.0001); support for clinical trials (p = 0.0001); ongoing BC trials at the physicians' institution (p = 0.003); currently prescribing HRT to women after BC (p = 0.03); and beneficial results in ongoing RCTs of HRT in well women (p = 0.02).
An RCT of short-term HRT after BC may be feasible among Canadian physicians.
为了成功招募患者参加一项大型随机对照试验（RCT），该试验旨在确定乳腺癌（BC）后短期激素替代疗法（HRT）的安全性和益处，需要医生的支持。
向1899名加拿大妇科医生、家庭医生、医学、放射和外科肿瘤学家邮寄了一份调查问卷，以评估他们将患者转诊至BC后HRT的RCT的意愿。
在538名医生中，420名（78%）报告他们愿意将BC后的女性转诊至HRT与安慰剂对照的RCT。预测转诊意愿的变量包括：对健康女性HRT的支持（p = 0.04）和BC后（p = 0.0001）；对临床试验的支持（p = 0.0001）；医生所在机构正在进行的BC试验（p = 0.003）；目前为BC后的女性开HRT处方（p = 0.03）；以及健康女性正在进行的HRT RCT中的有益结果（p = 0.02）。
在加拿大医生中，BC后短期HRT的RCT可能是可行的。
